IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 244 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $133 | -35.4% | 29,200 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $206 | +35.5% | 29,200 | +17.3% | 0.00% | 0.0% |
| Q1 2023 | $152 | -4.4% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $159 | -99.9% | 24,900 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $239,000 | -13.1% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $275,000 | -33.7% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $415,000 | -12.6% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $475,000 | -22.6% | 24,900 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $614,000 | -5.2% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $648,000 | -17.8% | 24,900 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $788,000 | -31.8% | 24,900 | 0.0% | 0.00% | -42.9% |
| Q4 2020 | $1,155,000 | +71.1% | 24,900 | +21.5% | 0.01% | +40.0% |
| Q3 2020 | $675,000 | -40.1% | 20,500 | -50.0% | 0.01% | 0.0% |
| Q2 2020 | $1,126,000 | – | 41,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 3,876,600 | $127,618,000 | 11.48% |
| Fairmount Funds Management LLC | 596,890 | $19,650,000 | 8.32% |
| Ghost Tree Capital, LLC | 575,000 | $18,929,000 | 5.47% |
| Perceptive Advisors | 10,085,632 | $332,019,000 | 4.85% |
| Avoro Capital Advisors LLC | 9,536,039 | $313,926,000 | 4.46% |
| FRAZIER MANAGEMENT LLC | 1,312,999 | $43,224,000 | 3.88% |
| ACUTA CAPITAL PARTNERS, LLC | 315,000 | $10,370,000 | 2.82% |
| Orbimed Advisors | 6,645,100 | $218,757,000 | 2.75% |
| QVT Financial LP | 572,971 | $18,862,000 | 2.30% |
| Prosight Management, LP | 120,606 | $3,970,000 | 1.89% |